European Journal of Cancer
Volume 42, Issue 15 , Pages 2492-2498 , October 2006

Numerous high-risk epithelial lesions in familial breast cancer

  • N. Hoogerbrugge

      Affiliations

    • Department of Human Genetics, From the Hereditary Cancer Clinic, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
    • Department of Medical Oncology, From the Hereditary Cancer Clinic, Radboud University Nijmegen Medical Centre, The Netherlands
    • Corresponding Author InformationCorresponding author: Tel.: +31 24 3616577; fax: +31 24 3565026.
    • ,
  • P. Bult

      Affiliations

    • Department of Pathology, From the Hereditary Cancer Clinic, Radboud University Nijmegen Medical Centre, The Netherlands
    • ,
  • J.J. Bonenkamp

      Affiliations

    • Department of Surgery, From the Hereditary Cancer Clinic, Radboud University Nijmegen Medical Centre, The Netherlands
    • ,
  • M.J.L. Ligtenberg

      Affiliations

    • Department of Human Genetics, From the Hereditary Cancer Clinic, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
    • Department of Pathology, From the Hereditary Cancer Clinic, Radboud University Nijmegen Medical Centre, The Netherlands
    • ,
  • L.A. Kiemeney

      Affiliations

    • Department of Epidemiology and Biostatistics, From the Hereditary Cancer Clinic, Radboud University Nijmegen Medical Centre, The Netherlands
    • ,
  • J.A. de Hullu

      Affiliations

    • Department of Obstetrics and Gynecology, From the Hereditary Cancer Clinic, Radboud University Nijmegen Medical Centre, The Netherlands
    • ,
  • C. Boetes

      Affiliations

    • Department of Radiodiagnostics, From the Hereditary Cancer Clinic, Radboud University Nijmegen Medical Centre, The Netherlands
    • ,
  • M.F. Niermeijer

      Affiliations

    • Department of Human Genetics, From the Hereditary Cancer Clinic, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
    • ,
  • H.G. Brunner

      Affiliations

    • Department of Human Genetics, From the Hereditary Cancer Clinic, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands

Received 27 January 2006 ,Revised 24 May 2006 ,Accepted 24 May 2006.

References 

  1. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20:2310–2318
  2. Armes JE, Venter DJ. Related articles, the pathology of inherited breast cancer. Pathology. 2002;34:309–314
  3. Breast Cancer Linkage Consortium . Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet. 1997;349:1505–1510
  4. Hoogerbrugge N, Bult P, de Widt-Levert LM, et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol. 2003;21:41–45
  5. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. New Eng J Med. 1985;312:146–151
  6. Singletary SE. Lobular carcinoma in situ of the breast: 31 year experience at the University of Texas, M.D. Anderson Cancer Center. Breast Dis. 1994;7:157–163
  7. Kauff ND, Brogi E, Scheuer L, et al. Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer. 2003;97:1601–1608
  8. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:159–164
  9. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22:1055–1062
  10. van Roosmalen MS, Stalmeier PF, Verhoef LC, et al. Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy. J Clin Oncol. 2002;20:2092–3000
  11. Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Onc. 2005;23:1656–1663
  12. Goldflam K, Hunt KK, Gershenwald JE, et al. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer. 2004;101:1977–1986
  13. Lostumbo L, Carbine N, Wallace J, Ezzo J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2004;(October 18):[CD002748]
  14. Metcalfe KA, Goel V, Lickley L, Semple J, Narod SA. Prophylactic bilateral mastectomy: patterns of practice. Cancer. 2002;95:236–242
  15. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62:676–689
  16. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer. 1994;73:643–651
  17. Egan RL. Multicentric breast carcinomas: clinical-radiographic-pathologic whole organ studies and 10-year survival. Cancer. 1982;49:1123–1130
  18. Holland R, Veling SH, Mravunac M, Hendriks JH. Pathologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer. 1985;56:979–990
  19. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long term follow-up study. Cancer. 1985;55:2698–2708
  20. Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum Pathol. 1992;23:1095–1097
  21. Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma-in-situ: a proposal for a new classification. Semin Diagn Path. 1994;11:167–180
  22. London SJ, Connolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer. JAMA. 1992;267:941–944
  23. Osborne MP, Borgen PI. Atypical ductal and lobular hyperplasia and breast cancer risk. Surg Oncol Clin N Am. 1993;2:1–11
  24. Fitzgibbons PL, Henson DE, Hutter RV. Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. Arch Pathol Lab Med. 1998;122:1053–1055
  25. Robson M, Svahn T, McCormick B, et al. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer. 2005;103:44–51
  26. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22:2328–2335
  27. Verhoog LC, Brekelmans CT, Seynaeve C, Meijers-Heijboer EJ, Klijn JG. Contralateral breast cancer risk is influenced by the age at onset in BRCA1 associated breast cancer. Br J Cancer. 2000;83:384–386
  28. Domchek SM, Stopfer JE, Rebbeck TR. Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers. J Natl Compr Canc Netw. 2006;4:177–182
  29. Sun CC, Lenoir G, Lynch H, Narod SA. In-situ breast cancer and BRCA1. Lancet. 1996;348:408
  30. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer. 2004;4:665–676
  31. Claus EB, Petruzella S, Matloff E, Carter D. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA. 2005;293:964–969
  32. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20:1480–1490
  33. Gilpin CA, Carson N, Hunter AG. A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. Clin Genet. 2000;58:299–308
  34. Berry DA, Iversen ES, Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002;20:2701–2712
  35. Adem C, Reynolds C, Soderberg CL, et al. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer. 2003;97:1–11
  36. Welch HG, Black WC. Using autopsy series to estimate the disease reservoir for ductal carcinoma in situ of the breast: how much more breast cancer can we find?. Ann Intern Med. 1997;127:1023–1028

PII: S0959-8049(06)00529-6

doi: 10.1016/j.ejca.2006.05.027

European Journal of Cancer
Volume 42, Issue 15 , Pages 2492-2498 , October 2006

Article Tools

* Image Usage & Resolution